Brief: Eiger Biopharmaceuticals Enters Into $75M Term Loan Agreement And $5M Stock Purchase Agreement With Innovatus Capital Partners To Refinance Existing Debt Facility And Further Strengthen Cash Position Ahead Of Key Milestones
07/06/2022 21:28
Eiger BioPharmaceuticals Inc EIGR.O :
* EIGER BIOPHARMACEUTICALS ENTERS INTO $75M TERM LOAN
AGREEMENT
AND $5M STOCK PURCHASE AGREEMENT WITH INNOVATUS CAPITAL PARTNERS
TO REFINANCE EXISTING DEBT FACILITY AND FURTHER STRENGTHEN CASH
POSITION AHEAD OF KEY MILESTONES
* EIGER BIOPHARMACEUTICALS - COMPANY EXPECTS ITS CASH, CASH
EQUIVALENTS, AND TOTAL INVESTMENTS TO FUND PLANNED OPERATIONS
THROUGH 2024
Source text for Eikon: ID:nPn23bz1na
Further company coverage: EIGR.O
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview